HRMY (Pharmaceuticals) Stock Valuation & Fair Value High quality, trading below fair value
HRMY (Pharmaceuticals) trades at a blended P/E of 11.6, about 27% below its historical normal valuation, with a forward growth estimate of 22.4% and a PEG of 0.52.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is HRMY overvalued?
At a blended P/E of 11.6 versus its historical normal P/E of 15.8, HRMY trades about 27% below its typical valuation, with a PEG of 0.52 on 22.4% forward growth. tickerseer currently rates it high quality, trading below fair value.
What is HRMY's fair value and PEG?
HRMY trades at a blended P/E of 11.6 against a historical normal P/E of 15.8, a PEG of 0.52, and a forward growth estimate of 22.4%.
Has tickerseer's rating of HRMY changed?
tickerseer's rating has been high quality, trading below fair value since 2026-07-31.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.